U.S. FDA Issues Warning Letter To Lupin Citing Manufacturing Deficiencies; Warns Products Will Not Be Approved Until Corrective Action
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - U.S. FDA issued a May 7 warning letter to Indian drug maker Lupin, that points at several unanswered issues raised by the drug regulator in earlier inspections at the company's Mandideep-based plant in India
You may also be interested in...
14 Months After U.S. FDA Charged India's Lupin, Manufacturing Facility At Mandideep Cleared
MUMBAI - A long trail of hair splitting audits and investigations came to an end for India's drug maker Lupin as U.S. FDA issued an "All Clear" statement for the company's Mandideep manufacturing site in the central Indian state of Madhya Pradesh
14 Months After U.S. FDA Charged India's Lupin, Manufacturing Facility At Mandideep Cleared
MUMBAI - A long trail of hair splitting audits and investigations came to an end for India's drug maker Lupin as U.S. FDA issued an "All Clear" statement for the company's Mandideep manufacturing site in the central Indian state of Madhya Pradesh
India’s Lupin Says Ready To Present Mandideep Plan To U.S. FDA; Push On Novel Drug Delivery, Biosimilars And Indian Market To Propel Revenue Growth
MUMBAI - Indian drug maker Lupin hopes to clear up issues with U.S. regulators on its Mandideep-based manufacturing unit, which has been issued warning letters by the U.S. FDA. The FDA had charged the facility deviated from current good manufacturing practices in the production of oral and injectable cephalosporins in November 2008